Information

Information

  1. Feb. 20, 2019

    Upsher-Smith Laboratories, LLC celebrates its 100-year anniversary. NEW

  2. Feb. 15, 2019

    Sawai Receives Approvals for Three Generic Drugs with Six Strengths [86KB/ pages] NEW

  3. Feb. 14, 2019

    Sawai Reports Third Quarter FY2018 Financial Results NEW

  4. Feb. 13, 2019

    An interview with Mitsuo Sawai (President of Sawai Pharmaceutical Co., Ltd.) was published in 2019 Japan Business Report in the South China Morning Post. NEW

  5. Jan. 09, 2019

    MHLW Approves New Indication for ARGATROBAN Injection [120KB/ pages]

  6. Dec. 13, 2018

    Sawai Launches Six Generic Drugs with 14 Strengths [298KB/ pages]

  7. Dec. 05, 2018

    MHLW Approves New Indication for RISEDRONATE Tablets and DOBUTAMINE I.V. Infusion [190KB/ pages]

  8. Nov. 21, 2018

    MHLW Approves New Indication for LEVOFOLINATE I.V. Infusion [181KB/ pages]

  9. Nov. 14, 2018

    IR "Summary of Financial Results for the 1st Half of FY2018"

    IR "Financial Results for the 1st Half of FY 2018"

  10. Oct. 24, 2018

    Upsher-Smith Launches Generic Version of ONFI® (Clobazam), CIV In Tablet And Oral Suspension Dosage Forms [145KB/ pages]

  11. Sep. 21, 2018

    Sawai Pharmaceutical Receives Public Knowledge-Based Applications for Anti-Cancer Agent OXALIPLATIN I.V. Infusion Solution for Additional Indication [219KB/ pages]

  12. Sep. 05, 2018

    MHLW Approves New Indication for ARIPIPRAZOLE Tablets 3 mg / 6 mg / 12 mg / 24mg [SAWAI] and ARIPIPRAZOLE Oral Solution 3 mg / 6 mg / 12 mg Packet [SAWAI] [221KB/ pages]

  13. Sep. 03, 2018

    Upsher-Smith Launches Generic Version of Lomotil® (Diphenoxylate Hydrochloride and Atropine Sulfate) Tablets [145KB/ pages]

  14. Aug. 16, 2018

    Sawai Pharmaceutical Receives Approvals for Six Compounds with 13 Strengths of Generic Drugs [90KB/ pages]

  15. Aug. 14, 2018

    IR "Summary of Financial Results for the 1st Quarter of FY2018"

    IR "Financial Results for the 1st Quarter of FY2018"

  16. Aug. 08, 2018

    Upsher-Smith Launches Bexarotene Capsules [145KB/ pages]

  17. Jul. 17, 2018

    Upsher-Smith Launches Vigabatrin for Oral Solution Under the Brand Name Vigadrone™ [146KB/ pages]

  18. Jun. 20, 2018

    Announcement on Completion of Transfer of Manufacturing and Marketing Approval of Zomig® Tablets 2.5 mg and Zomig® RM Tablets 2.5 mg, Migraine Treatment [129KB/ pages]

  19. Jun. 14, 2018

    Sawai Pharmaceutical Launches 7 Compounds with 17 Strengths of Generic Drugs [211KB/ pages]

  20. Jun. 06, 2018

    MHLW approves New Indication for OSELTAMIVIR Capsules 75mg [SAWAI] / Dry Syrup 3% [SAWAI] [230KB/ pages]

  21. May. 25, 2018

    Sawai Pharmaceutical Submits Public Knowledge-Based Application for Anti-Cancer Agent OXALIPLATIN I.V. Infusion Solution for Additional Indication [217KB/ pages]

  22. May. 15, 2018

    IR "Medium-Term Business Plan (M1 TRUST 2021)"

    IR "Summary of Financial Results for FY 2017"

    IR "Financial Results for FY 2017"

    Announcement on Personnel Changes [147KB/ pages]

  23. May. 10, 2018

    UPSHER-SMITH LAUNCHES DOXAZOSIN TABLETS, USP [139KB/ pages]

  24. Apr. 04, 2018

    MHLW approves New Indication for OLANZAPINE formulation and New Administration for MEROPENEM formulation [312KB/ pages]

  25. Mar. 26, 2018

    Announcement on Organizational Changes and Personnel Changes [286KB/ pages]

  26. Mar. 20, 2018

    MHLW approves New Indication for PRAMIPEXOLE HYDROCHLORIDE Tablets 0.125mg “SAWAI” / 0.5mg “SAWAI” [287KB/ pages]

  27. Feb. 15, 2018

    Sawai Pharmaceutical receives approvals for 8 compounds with 19 strengths of generic drugs [188KB/ pages]

  28. Feb. 13, 2018

    IR "Summary of Financial Results for the 3rd Quarter of FY2017"

    IR "Financial Results for the 3rd Quarter of FY2017"

  29. Nov. 13, 2017

    Sawai Pharmaceutical Forms Strategic Alliance with Sumitomo Corp in the US Generics Market

    IR "Summary of Financial Results for the 1st Half of FY2017"

    IR "Financial Results for the 1st Half of FY 2017"

  30. Aug. 14, 2017

    IR "Summary of Financial Results for the 1st Quarter of FY2017"

    IR "Financial Results for the 1st Quarter of FY2017"

Information
Back to Top